Literature DB >> 15950283

Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.

Janet F Piskurich1, Carolyn A Gilbert, Brittany D Ashley, Mojun Zhao, Han Chen, Jian Wu, Sophia C Bolick, Kenneth L Wright.   

Abstract

The MHC class II transactivator (CIITA), the master regulator of MHC class II (MHC II) expression, is a co-activator that controls MHC II transcription. Human B lymphocytes express MHC II constitutively due to persistent activity of CIITA promoter III (pIII), one of the four potential promoters (pI-pIV) of this gene. Although increases in MHC II expression in B cells in response to cytokines have been observed and induction of MHC II and CIITA by IFN-gamma has been studied in a number of different cell types, the specific effects of IFN-gamma on CIITA expression in B cells have not been studied. To investigate the regulation of CIITA expression by IFN-gamma in B cells, RT-PCR, in vivo and in vitro protein/DNA binding studies, and functional promoter analyses were performed. Both MHC II and CIITA type IV-specific RNAs increased in human B lymphocytes in response to IFN-gamma treatment. CIITA promoter analysis confirmed that pIV is IFN-gamma inducible in B cells and that the GAS and IRF-E sites are necessary for full induction. DNA binding of IRF-1 and IRF-2, members of the IFN regulatory factor family, was up-regulated in B cells in response to IFN-gamma and increased the activity of CIITA pIV. In vivo genomic footprint analysis demonstrated proteins binding at the GAS, IRF-E and E box sites of CIITA pIV. Although CIITA pIII is considered to be the hematopoietic-specific promoter of CIITA, these findings demonstrate that pIV is active in B lymphocytes and potentially contributes to the expression of CIITA and MHC II in these cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950283      PMCID: PMC1482792          DOI: 10.1016/j.molimm.2005.05.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  57 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  The bare lymphocyte syndrome and the regulation of MHC expression.

Authors:  W Reith; B Mach
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 3.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.

Authors:  N Ghosh; I Gyory; G Wright; J Wood; K L Wright
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

6.  BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.

Authors:  J F Piskurich; K I Lin; Y Lin; Y Wang; J P Ting; K Calame
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

7.  A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes.

Authors:  N Ghosh; J F Piskurich; G Wright; K Hassani; J P Ting; K L Wright
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

8.  Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter.

Authors:  X S Zhu; M W Linhoff; G Li; K C Chin; S N Maity; J P Ting
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

9.  Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression.

Authors:  S Landmann; A Mühlethaler-Mottet; L Bernasconi; T Suter; J M Waldburger; K Masternak; J F Arrighi; C Hauser; A Fontana; W Reith
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

10.  MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?

Authors:  W Walter; K Lingnau; E Schmitt; M Loos; M J Maeurer
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  16 in total

1.  Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.

Authors:  Giovanna Butticè; Janice Miller; Lin Wang; Barbara D Smith
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

2.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

3.  Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels.

Authors:  Andrew W Lee; Nan Wang; Tara M C Hornell; James J Harding; Chetan Deshpande; Laura Hertel; Vashti Lacaille; Achal Pashine; Claudia Macaubas; Edward S Mocarski; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2011-03-31       Impact factor: 4.407

4.  Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.

Authors:  Han Chen; Carolyn A Gilbert; John A Hudson; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2006-06-12       Impact factor: 4.407

5.  Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.

Authors:  Matthew A Smith; Gabriela Wright; Jian Wu; Prafullakumar Tailor; Keiko Ozato; Xianghong Chen; Sheng Wei; Janet F Piskurich; Jenny P-Y Ting; Kenneth L Wright
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

6.  MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Authors:  Mojun Zhao; Frederick L Flynt; Mei Hong; Han Chen; Carolyn A Gilbert; Nicole T Briley; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

7.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Authors:  Kelly A Cycon; Kathleen Mulvaney; Lisa M Rimsza; Daniel Persky; Shawn P Murphy
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

8.  IFNγ and GM-CSF control complementary differentiation programs in the monocyte-to-phagocyte transition during neuroinflammation.

Authors:  Ana Amorim; Donatella De Feo; Ekaterina Friebel; Florian Ingelfinger; Cyrill Dimitri Anderfuhren; Sinduya Krishnarajah; Myrto Andreadou; Christina A Welsh; Zhaoyuan Liu; Florent Ginhoux; Melanie Greter; Burkhard Becher
Journal:  Nat Immunol       Date:  2022-01-31       Impact factor: 31.250

9.  The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.

Authors:  Petra D Cravens; Bernd C Kieseier; Rehana Hussain; Emily Herndon; Benjamine Arellano; Li-Hong Ben; Brenda C Timmons; Cyd Castro-Rojas; Hans-Peter Hartung; Bernhard Hemmer; Martin S Weber; Scott S Zamvil; Olaf Stüve
Journal:  J Neuroinflammation       Date:  2013-05-24       Impact factor: 8.322

10.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.